12:09 PM EST - AEterna Zentaris Inc : Announced that sales of Macrilen® will be temporarily discontinued in the United States commercial market for the diagnosis of adult growth hormone deficiency, effective May 23, 2023 and until anticipated re-launch with an alternate commercialization partner. This temporary action follows the August 29, 2022 announced decision by Aeterna’s former North American commercialization partner Novo Nordisk Healthcare AG to end its license agreement for this product in North America. The Company is actively seeking alternate development and commercialization partners for Macrilen® in the US and other territories currently not partnered. AEterna Zentaris Inc
shares T.AEZS are trading -$0.09 at $3.26.
